Array Biopharma Inc.

Genentech, Inc.

Genetech, Inc.

Covenentech, Inc.

Genertech, Inc.

Tang, Tony P.

Hentemann, Martin F.

Blake, James F.

Banka, Anna

Wallace, Eli M.

Bencsik, Josef R.

Mitchell, Ian S.

Xu, Rui

Sammond, Douglas Mccord

Fong, Kin Chiu

Josef R Bencsik

James F Blake

Rui Xu

Ian S Mitchell

Nicholas C Kallan

Jun Liang

Dengming Xiao

Keith Lee Spencer

Brian Salvatore Safina

Eli M Wallace

Stephen T Schlachter

Christine Chabot

Anna L Banka

Martin F Hentemann

Tony P Tang

Steven Huy Do

Birong Zhang

James M Graham

Kin Chiu Fong

Jun M Li

Mike Welch

Jun Li

Douglas McCord Sammond

Anna L Leivers

Eli W Wallace

AnnaL Banka

StephenT Schlachter

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof.  Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Pyrimidyl cyclopentanes as AKT protein kinase inhibitors

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I:  Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors

The present invention provides compounds of Formula I including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof.  Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

Pyrimidyl cyclopentanes as Akt protein kinase inhibitors

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula:  Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Substituted piperazines as AKT inhibitors

Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors

The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer. 

Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer. 

Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors

The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. 

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. 

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I). 

5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. 

Dihydrofuro pyrimidines as AKT protein kinase inhibitors

Growing community of inventors

Longmont, CO, United States of America

Josef R Bencsik